報價延遲最少15分鐘:2025/04/12 04:12 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.38 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.32/-2.81
|
|
企業價值
351.76M
|
| 資產負債 |
|
每股賬面淨值
4.90
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
43.27M
|
|
每股收益
0.62
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/12 04:12 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |